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The most replicated neuroanatomical finding in autism is the tendency toward brain
overgrowth, especially in younger children. Research shows that both gray and white
matter are enlarged. Proposed mechanisms underlying brain enlargement include
abnormal inflammatory and neurotrophic signals that lead to excessive, aberrant
dendritic connectivity via disrupted pruning and cell adhesion, and enlargement of
white matter due to excessive gliogenesis and increased myelination. Amyloid-β protein
precursor (βAPP) and its metabolites, more commonly associated with Alzheimer’s
disease (AD), are also dysregulated in autism plasma and brain tissue samples.
This review highlights findings that demonstrate how one βAPP metabolite, secreted
APPα, and the ADAM family α-secretases, may lead to increased brain matter, with
emphasis on increased white matter as seen in autism. sAPPα and the ADAM
family α-secretases contribute to the anabolic, non-amyloidogenic pathway, which
is in contrast to the amyloid (catabolic) pathway known to contribute to Alzheimer
disease. The non-amyloidogenic pathway could produce brain enlargement via genetic
mechanisms affecting mRNA translation and polygenic factors that converge on
molecular pathways (mitogen-activated protein kinase/MAPK and mechanistic target
of rapamycin/mTOR), promoting neuroinflammation. A novel mechanism linking the
non-amyloidogenic pathway to white matter enlargement is proposed: α-secretase
and/or sAPPα, activated by ERK receptor signaling activates P13K/AKt/mTOR and then
Rho GTPases favoring myelination via oligodendrocyte progenitor cell (OPC) activation
of cofilin. Applying known pathways in AD to autism should allow further understanding
and provide options for new drug targets.
Keywords: amyloid, anabolic, brain overgrowth, biomarker, comorbidity, metabolites, neurodevelopmental,
secretase
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INTRODUCTION
Autism or Autistic Syndrome Disorder (ASD) is characterized
by lack in social communication and interaction and by
restricted/repetitive patterns of interests, behaviors or
activities (DSM-5) (1). It is considered the fastest growing
neurodevelopmental disability. ASD prevalence estimates
from the Centers for Disease Control (CDC) in 2014 were
1 in 68 children, which was up 30% from that reported in
2008, and more than double the frequency from 2000 (2).
Autism affects more boys than girls. There is no agreed
upon biomarker for ASD, however, the most replicated
neuroanatomical finding is the tendency for heads and brains
to be large, especially in young ASD subjects (3–7). Both
macrocephaly—enlarged heads, as measured by occipital-frontal
circumference (OFC), and megalencephaly, or enlarged brains,
as measured post mortem or by MRI, are reported in autism.
It is possible to have macrocephaly without megalencephaly.
Unfortunately, the two are at times confused in the literature.
Megalencephaly is increased growth of cerebral structures
related to anomalies during brain development or because
of postnatal abnormal events that cause excessive cerebral
growth. On the other hand, macrocephaly, or simple increased
head circumference, is linked to various events that are not
necessarily neurological, including anomalies of bone skull
structures, subdural fluid collections, hydrocephalus, intracranial
masses, and arteriovenous malformations (8). However, only
20% of individuals with autism have enlarged brains (9), and
the association between macrocephaly and core features of
autism remains weak. This opens the door to entertain novel
associations or apply knowledge from better-developed fields
such as Alzheimer Disease (AD) to the study of autism.
AD comprises up to 80% of all dementias, affects 1 in
10 individuals over the age of 65, and affects more women
than men (10). The amyloid hypothesis predicts clinical disease
associated with amyloid-β loaded plaques resulting in brain
atrophy in individuals with AD. Amyloid-β protein precursor
(βAPP) and its metabolites are dysregulated in autism (11–
15). βAPP is a large membrane spanning glycoprotein with a
long extracellular N-terminus, a transmembrane region and an
intracellular C-terminus, the βAPP intracellular domain [AICD;
(16)]. After translation in the endoplasmic reticulum, APP
undergoes post-translational modification in the Golgi complex
before it travels to the cell membrane (17). The mature protein
undergoes proteolytic cleavage by a combination of secretase
enzymes. β- and γ-secretases generate amyloid-β (Aβ) peptides,
primarily Aβ-40 and 42, found in the cerebral amyloid plaques
of AD along with secreted APPβ (sAPPβ). α- and γ-secretase
produce sAPPα, which is generally considered neurotrophic
and neuroprotective, as well as AICD and p3 peptide. Under
normal conditions, a small fraction of secreted βAPP is sAPPβ,
produced via the amyloidogenic pathway. The majority of
secreted product consists of sAPPα, produced constitutively via
the non-amyloidogenic pathway. In AD, Aβ peptide is secreted
at high levels and accumulates as neurotoxic extracellular
aggregates. βAPP localizes to somatodendritic, axonal and the
presynaptic active zones (18). βAPP expression is upregulated
during inflammation (19) and is activated by proinflammatory
cytokines and astrocytes (17, 20), so that APP may be involved in
the acute phase protein response to immune stress. In synopsis,
the localization of βAPP at dendritic synapses, its role in cell
adhesion, its interaction with post-translational pathways and in
transcription suggests that βAPP metabolites may play a pivotal
role in the development of autism, and its single gene model kin,
Fragile X Syndrome (FXS) (21, 22).
In this article we demonstrate how βAPP, particularly
the non-amyloidogeneic pathway involving sAPPα contributes
to the following mechanisms underlying excessive brain
growth in autism: neuroinflammation, including cytokine
activation, translational pathways, and increased myelination.
These mechanisms were chosen as they are important to βAPP
processing in AD, and serve to demonstrate catabolic vs. anabolic
forces underlying these disorders.
In two independent studies (11, 21), our group has reported
higher sAPPα levels and lower Aβ peptide levels in plasma of
children with autism (n = 26). The same pattern was seen
in autism temporal lobe brain tissue (n = 7) (21) of children
with autism. The sAPPα results have been replicated by an
independent laboratory in autism serum (15) and brain tissue
(23). The finding of increased sAPPα also has been reported
via confocal microscopy of brain tissue from groups of children
with duplication 15q11.2-q13 and idiopathic autism (24). We
have found increased levels of sAPPα, βAPP, and Aβ plasma
markers in children with FXS (n = 12) compared to those
with autism (n = 11) and typical development (n = 18),
and in brain tissue from individuals with FXS [n = 3; (21)].
One of the purported α-secretase enzymes that cleaves βAPP
and generates sAPPα (25), A Disintegrin and Metalloproteinase
Domain 17 (ADAM17) also known as tumor necrosis factor-
α converting enzyme (TACE), increases in autism brain tissue
(21). ADAM17 is a member of the adamalysin family sheddases,
and together with ADAMs 9 and 10, cleaves APP at the
alpha-secretase site (26). Further, ADAM17 is pro-inflammatory,
as it releases the cytokine tumor necrosis factor-α (TNF-α)
during inflammation (27). ADAM17 and ADAM10 are essential
for development of oligodendrocytes (28, 29), which produce
myelin within the CNS. Several studies in the field point
to a connection between differences in βAPP processing and
autism (Table 1).
In total, these findings support the “Anabolic Hypothesis
of βAPP in Autism” (14, 32), which postulates that sAPPα
contributes to neuronal and glial overgrowth in the brain
resulting in neuronal interference contributing to autism
symptoms. One direct mechanism has been reported by
Westmark and Malter (33) who found that βAPP is regulated
via Fragile X Mental Retardation Protein (FMRP) via mGluR-5
in mouse models of FXS. When the FMRP “brake” is removed
in translation, βAPP mRNA is increased. Of note, children with
FXS often display macrocephaly, with a predominance of white
matter (34). βAPP and metabolites play an anabolic role in other
translation regulating pathways such as Mammalian target of
rapamycin [mTOR; (35)], Ras small GTPase/Extracellular signal
regulated kinase [Ras/ERK; (36, 37)] and phosphoinositol 3
kinase/mammalian target of rapamycin [P13k/mTOR; (37, 38)].
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TABLE 1 | Studies linking βAPP with autism.
Study Subjects/materials Finding
Lahiri et al. (30) Brain samples from TD, AD, ASD, and
FXS human subjects
Elevated βAPP and Aβ in FXS and AD, reduced Aβ and elevated sAPPα
in ASD subjects, all vs. age-matched controls.
Ray et al. (21) Plasma from TD, ASD, and FXS human
subjects
Aβ and sAPPβ levels reduced and sAPPα elevated in ASD while Aβ and
βAPP elevated in FXS, all vs. controls.
Ray et al. (13) Plasma from TD, mild/moderate ASD,
severe ASD human subjects
Aβ and sAPPβ levels reduced and sAPPα elevated in severe but not
mild/moderate ASD vs. controls
Sokol et al. (11) Plasma from TD, mild/moderate ASD,
severe ASD human subjects
Aβ40 and Aβ42 levels diminished according to severity of autism (more
severe→ lower levels). Secreted APP increased alongside autism
severity.
Bailey (15) Whole blood samples from autism
subjects and age-matched TD controls,
human umbilical cord blood
sAPPα elevated in whole blood and plasma of autistic children. 7% of
undiagnosed cord blood samples had elevated sAPPα
Wegiel et al. (24) Brain samples from TD, ASD, and dup(15)
human subjects
dup(15) subjects accumulated high levels of p3 peptide. ASD subjects
had intermediate accumulation of P3, while controls had lowest levels of
accumulated p3.
Bailey et al. (31) Blood from human sAPPα overexpressing
mice
sAPPα elevation corresponded to elevated CD8+ T cells and decreased
effector memory T cells. Multiple signal and cytokine levels were also
perturbed.
This sets the stage for the discussion of gray and white matter
enlargement in autism, with the potential contribution from
βAPP metabolites.
NORMAL BRAIN GROWTH
Mammalian brain cells include neurons and glia. Neuron cell
bodies and dendrites form the outer gray matter, with axons
projecting downward into the subcortical white matter. Brain
size depends both on the size of the cerebral cortex or gray
matter and the underlying white matter (39). The volume of
gray cortex is determined by cortical thickness, and cortical
surface area, believed to be genetically independent (40). One
model to explain cortical thickness and surface area pertains to
radial cortical columns (41). Radial cortical columns depend on
the number of neural stem cells that symmetrically divide in
the ventricular zone before neurogenesis (39). The growth of
progenitor cells predicts the number of neurons within the radial
columns (42). Cortical thickness is predicted by the number
of cells within the columns, whereas surface area is predicted
by the number of cortical columns (41). The white matter
comprises over half the human brain, in greater proportion than
other animals (43). Intensely studied in demyelinating conditions
such as multiple sclerosis, myelin, and white matter structure is
dynamic, regulated by impulse activity, and essential to cognitive
function (5, 43–45). Besides neuronal axons, white matter is
composed of glia. Glia are of three types including: (1) astrocytes,
which outnumber neurons five to one (46), contribute to synaptic
transmission, neuronal processing (46) and form the blood brain
barrier; (2) microglia, which act as innate immune cells providing
host defense and tissue repair-these release cytokines, nitric
oxide and various neurotrophic factors; and (3) oligodendrocytes
which manufacture myelin sheaths for axonal insulation. The
precursor to oligodendrocytes are oligodendrocyte precursor
cells (OPCs), which are the only type of glia to receive
synaptic input from neurons (44). OPCs produce neuron/glia
antigen 2-NG2, which communicate directly with neurons and
demonstrate the newly appreciated importance of glia, which
seem to “talk back to neurons” (46). Glia are found in both gray




In 1943, Leo Kanner (48) observed that some autistic children
have large heads. Subsequent observations showed a strong trend
toward enlarged OFC in autism, particularly in younger subjects
(3, 49–51). However, individual reports must be evaluated
carefully, since evaluations based on standard growth curves
can give drastically different results depending on the specific
curve. For example, a survey of over 75,000 neonatal OFC
from infants in a single US-based primary care network (PCN)
found macrocephaly in 8.6% according to CDC curves, in
14% according to the World Health Organization (WHO)
curves, and in 5.1% according to National Center of Health
Statistics (NCHS) curves. If the norm was the PCN’s own
distribution, only 4.4% had OFC > 95th percentile (52). Studies
that compare autistic and non-autistic groups directly should
be considered more reliable than other studies (51, 53, 54).
Indeed, use of population norms may have introduced systematic
age-dependent bias into nearly 83% of the field’s studies on
head circumference (HC) vs. autism (54). The effect of autism
vs. other known influences on head size also may have been
chronically over-stated. A systematic review of ∼400,000 HC
measures on ∼75,000 children found that when models also
included covariates known to strongly influence HC regardless of
autism, such as parental height and parental HC, the covariates
played a large role in child HC even when the parents were
not themselves autistic. In addition, the best-replicated aspects
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of early brain overgrowth across studies were more reflective of
biases in HC norms than specific ASD traits or biomarkers (54).
In a specific study, once gender, age, height, weight, and parental
contribution were taken into account, the contribution of autism
came to an overall effect of+2 millimeters. This small effect was,
however, significant (53).
Nevertheless, in properly designed, control-matched studies,
autism still associates with macrocephaly, even though most
autistic children are not macrocephalic. Compared to typical
development, autistic brains show a growth spurt shortly after
birth, continuing in the first year of life, suggesting postnatal
pathology. Neuropathological evidence of brain overgrowth
include increased brain size and weight (55–57) and the early
migration of pyramidal cells with more numerous, smaller,
and less compact minicolumns (58–60). Minicolumns, described
as vertical groups of large neurons flanked by cell-sparse
surroundings, would require the growing support of short-
range fibers that make up the white matter without affecting
neuron density, as the brain grows larger (61). Large brains
have been noted in autism, particularly in children <4 years
of age, in cross sectional MR brain volumetry studies (3, 4,
62–64). Autism investigators have reported increases in total
cerebral volume (64–66), cortical thickness (54), cortical surface
area (39, 67), regional gray (60, 65, 68), and white matter
(44, 69). A recent volumetric MRI longitudinal study of 200
children with autism identified 15% of this sample as boys
with large heads disproportionate to height or “disproportionate
megalencephaly” (70). Further study of this megalencephalic
cohort revealed increased surface area but not increased cortical
thickness (39), as well as increased white matter of the
brain (70).
At young ages (2–6 years), brain enlargement occurs
seemingly coincidental with the display of autistic symptoms
(62, 69). This is followed by abnormal decline in brain growth
by 12–16 years (71). This raises the question if genetic growth
factors/neuroinflammation can cause early brain enlargement
resulting in later destruction. Further, brain enlargement appears
to be greatest in the frontal and temporal cortices and
amygdala and least in the occipital regions. This corresponds
to known deficits in autism in social skills (frontal lobes),
language and communication (temporal lobes), and emotional
control (amygdala) with sparing of the visual spatial abilities
(occipital lobe) (71).
Few studies to date have undertaken cellular analysis
to determine the neural underpinnings of brain overgrowth
in autism. For example, an increased number of neurons
in autism prefrontal gray matter could contribute to brain
overgrowth (71). This study raises the possibility that a
prenatal cause of autism as neurogenesis is complete before
birth in prefrontal cortex and all of cerebral cortex (72)
However, no similar studies have been performed on white
matter. Myelin and white matter continue to develop until the
third decade, which involves processes other than increased
number of neurons, such as gliogenesis and myelination, as
shown by mutations of the phosphatase and tensin homolog
(PTEN) gene associated with autism and macrocephaly (73), as
discussed below.
Functional Correlations of Increased Brain
Growth in Autism
The functional correlates of enlarged brains in autism have
eluded researchers. Early autism studies showed no association
between macrocephaly and clinical function such as IQ or
seizure frequency (9, 74), whereas in others, macrocephaly was
associated with higher function (50, 75). However, IQ and
seizure frequency are not core traits of autism. Instead, it may
be that macrocephaly associates more strongly with specific
endophenotypes within the autism spectrum, rather than autism in
general. For example, within autistic boys (but not girls), greater
HC associated with higher (more dysfunctional) scores in the
Autism Diagnostic Interview-Revised (ADI-R) social algorithm
scale (9). Further evidence that HC may correspond to different
autism subtypes is that the HC of boys with regressive autism
was significantly greater than non-autistic boys or boys with non-
regressive autism. No HC differences were found for girls vs.
regression (64).
Regional brain enlargement also is associated with higher
function: enlarged amygdala in young children with autism, ages
2–4, was associated with joint attention ability, a core clinical
feature of autism (76), and the larger volume of corpus callosum
in younger preschool children was associated with lower severity
of autism core symptoms (77). However, enlarged amygdala
in autism does not necessarily entail macrocephaly (78). In a
more comprehensive study of adults with autism with average
intelligence (68), both cortical thickness and voxel based volume
measurements identified enlarged gray matter regions that are
associated with autism core features including the inferior
frontal cortex, superior temporal sulcus, cingulate gyrus, middle
occipital gyrus, fusiform gyrus, and inferior parietal lobule, which
are associated with social abilities; superior temporal sulcus and
inferior frontal gyrus, which are associated with communication;
and orbital frontal gyrus and anterior cingulate gyrus, which
are associated with repetitive behaviors. In particular, boys with
disproportionate megalencephaly and autism had more severe
disabilities, and a poorer prognosis (65), language deficits (79),
and showed more regression (64). Large brains in autism may
be responsible for more global deficits such as weak coherence
theory, the ability to understand context or the “big picture,”
instead of more discrete autism core features (44).
MECHANISMS OF BRAIN OVERGROWTH
IN AUTISM
Mechanisms of Increased Cortical Gray
Matter in Autism
As stated above, cortical thickness is predicted by the number of
neurons within the radial cortical columns, whereas surface area
is predicted by the number of cortical columns (41). Casanova
et al. (58, 60) have reported reduction in minicolumn width
and neuropil spacing in layer III neocortex reflecting an increase
in minicolumns in autism. β-catenin and caspase 3/9 proteins
have been implicated in cortical surface area. Transgenic mice
expressing β-catenin develop an increased number of progenitor
cells in the ventricular zone which leads to more cortical radial
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columns and increased surface area (80). Caspase 3/9 mutations
result in decreased apoptosis of progenitor and radial glial
cells, which increase surface area (81). Although this paper
proposes a relationship between anabolic βAPP and increased
white matter in autism, there are mechanisms potentially linking
βAPP to increased gray matter as well. For example, βAPP shows
reciprocal regulation of the anabolic Wnt/β-catenin signaling
pathway, and βAPP physically interacts with β-catenin (82).
Furthermore, βAPP decreases apoptosis in part by decreasing
Caspase 3/9 by means of the phosphoinositide 3-kinase and
Protein kinase B (PI3K/AKT) pathway in AML1-ETO positive
(AE) leukemia (83). As described below, the contribution of
βAPP to the PI3K/AKT pathwaymay be involved in white matter
growth in autism.
Mechanisms of Increased Cortical White
Matter in Autism
Autism has been described as a disorder of brain connectivity
(84) and therefore the white matter, subjacent to gray matter
cortex, which connects discreet cortical regions, is a region
of interest. Increased white matter in autism exists in whole
brain and cerebellum (62), in radiate outer zones (6), and in
specific brain regions (85–88). Herbert (44) observed larger
cerebral white matter volume in children with autism as well
as in children with developmental language disorders. This was
replicated in a larger sample of children with autism compared
to control groups of children with benign macrocephaly and
reading disability (89). Newer imaging techniques such as
diffusion tensor imaging (DTI) have uncovered differences in
white matter tract microstructure in autism (90–92). A review of
cross sectional DTI in autism showed results consistent with an
abundance of local, short white matter connections within lobes
(e.g., temporal lobes) and reduced long distance connections
(corpus callosum) between lobes (93, 94). Although white matter
tracts appear disrupted in autism, the neuropathology underlying
the disruption is not clear fromDTI studies (93). Recent review of
DTI longitudinal studies showed increased fractional anisotropy,
ameasure of whitematter integrity, at 6months of age, remaining
atypical until 24 months of age and a reduced rate of white matter
growth in late childhood-early adolescence in the left parietal, left
occipital and bilateral temporal lobes (88). Hypermetabolism, as
measured by fluorodeoxyglucose positron emission tomography
(PET), was found for white matter within the internal capsule,
corpus callosum, frontal, and temporal lobes of young adult
subjects with autism, similar to patients with schizophrenia (95).
This was explained by disruption of myelination (95). Altogether
these results suggest at least a transient increase in white matter
volume that may recede over time.
We propose that βAPP metabolites may contribute to
mechanisms of increased white matter in autism. Thus, we
discuss neuroinflammation, cytokine release, translation
pathways and increased myelination. In contrast to increased
neurons found in autism gray matter (71), neuroinflammation
[including astrogliosis and microgliosis; (96, 97)], along with
increased myelination, may contribute more to the white
matter enlargement in autism (43, 44, 94). Genetic mechanisms
proposed to cause macrocephaly and autistic traits include
genes affecting mRNA translation pathways (98). Many factors,
including neuroinflammation and polygenic factors may
converge on molecular pathways (mitogen-activated protein
kinase -MAPK and mechanistic target of rapamycin- mTOR),
which could explain significant features of ASD, including
white matter enlargement. In this review, we propose that
secreted amyloid precursor protein metabolites, particularly
sAPPα, contribute to ASD white matter enlargement, ultimately
through MAPK and protein translation pathways that may
stimulate increased gliosis and/or myelination This is a novel
application of pathways developed for AD which may invite new
understanding and treatment for autism.
NEUROINFLAMMATORY EFFECTS
Neuroinflammation in Autism
How can neuroinflammation contribute to brain overgrowth in
autism? Up until 2005, it had been assumed that autism did
not involve an inflammatory process, as there were no reports
of gliosis or replicable inflammation in neuropathologic studies
or brain MRI (44). By using immunochemistry and cytokine
protein arrays, Vargas first showed an increase in CSF level
cytokines (macrophage chemoattractant protein-1 and tumor
growth factor β1) and microglia-astroglial activation (increased
glial fibrillary acidic protein-GFAP) in the medial frontal gyrus
and cerebellum in children and adults with autism (96). Further
studies showed microglial pathology in autism (60, 99, 100).
Specific decrease in ramifiedmicroglia (said to underlie deficits in
synaptic pruning) and increase in primed microglia (associated
with chronic inflammation) were found in autistic gray and
white matter (97). Neuroinflammation in autism appears to be
similar to AD (44) showing microscopic but not MRI signs
of inflammation. Confocal microscopy study of children with
idiopathic autism and dup15q11.2-q13 revealed that p3 peptide
(a neurotrophic, non-amyloidogenic βAPP processing product)
aggregates in astrocytes and microglia (24). Using confocal
microscopy, specific antibodies identified higher equivalents of
sAPPα in gray and white matter structures for dup15q11.2-q13,
followed by idiopathic autism, followed by typical controls.
Reports exist of peripheral blood abnormalities involving
T-cell, B-cell, autoantibody production, and increased pro-
inflammatory cytokines (101), but these studies were limited
by cross sectional design, small sample size, subjects of
different ages, and lack of standardized diagnosis. A recent
longitudinal study of serum (with typically developing controls)
and cerebrospinal fluid (no controls) from young children
with autism (ages 2–8) surprisingly found no evidence of
immunemediators supportive of active systemic inflammation in
autism (102). Only “modulators of immune function,” Epidermal
Growth Factor (EGF) and soluble CD40 ligand were increased
in autism serum (102). The authors concluded that this was
due to a “genetically determined growth or immune-modulatory
dysregulation” rather than an active systemic inflammatory
response (102). The following CSF immune mediators were
elevated: FLT3L, IL-15, CX3CL1, CXCL8, and CCL2, and
their role interpreted as homeostatic in support of microglia
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rather than an adaptive neuroinflammatory response. The
biggest finding was the lack of overlap between peripheral
and cerebrospinal markers and of serum markers over time,
demonstrating no reliable peripheral biomarker (102).
Given the possibility of a genetically upregulated immunity
in autism, how would this produce brain overgrowth? Herbert
(44) suggests that white matter volume increase is due to cell
swelling/tissue volume increase as a result of activated microglia
and astroglia, or via a compensatory increase in vascularization.
Neuroinflammation could trigger cytokine or chemokine
release (44), as identified by Pardo (102), or other secondary
signaling pathways such as mTor-PI3-Akt. Alternatively,
neuroinflammation could lead to increased excitotoxicity with
increased oligodendrocyte activity leading to an increase in
myelination. Persistent, chronic neuroinflammation over time
could then lead to cell death. This would explain the longitudinal
changes of overgrowth followed by decrease in growth in autism
brain MRI studies. Altogether, this sets the stage for the role
βAPP metabolites may play in neuroinflammation, cytokine
activation, and excessive myelination in autism.
Neuroinflammation and βAPP
AD is a neurodegenerative disorder characterized by ongoing,
permanent memory impairment and dementia. It is construed
as a multifactorial disease affected by genetic and environmental
factors. Neuroinflammation, vascular compromise and free
radical damage lead to the abnormal accumulation of cerebral
Aβ peptide and ultimately death (103). Alpha secretase, now
believed to be ADAM10 or ADAM17, constitutively cleaves
βAPP to produce sAPPα, p3 peptide, and AICD along the
non-amyloidogenic (neurotrophic) pathway. The β-amyloid
hypothesis states that improper cleavage yields Aβ peptides found
in the cerebral amyloid plaques of AD. Early in the disease,
microglia are protective, increasing the phagocytic clearance
of Aβ peptides. However, overtime, microglia become more
catabolic producing proinflammatory cytokines IL-1 and TNF-
α with the latter being more detrimental, eventually leading to
brain atrophy seen in AD. Inflammatorymediators, in turn, cause
more Aβ production (104). Evidence supports sAPPα activity on
microglial cells, activating release of IL-1 (105), glutamate and
inflammatory markers (106, 107). Treatment of neural stem cells
with recombinant sAPPα led to increased astrogliogenesis (108).
Treatment with sAPPα differentiates neuronal progenitor cells
into astroglia (109).
ADAM17is one of the alpha secretases that is active in AD.
It is found in higher levels in the CSF of patients with AD and
its precursor Mild Cognitive Impairment (MCI) (110). ADAM-
17 positive neurons are often found together with amyloid
plaques in AD brains, suggestive that ADAM17 is involved in
AD pathogenesis (111). ADAM17 produces neurotrophic sAPPα
following the non-amyloidogenic pathway, but also contributes
to the neuroinflammation in AD microglial activation (112).
ADAM17, therefore, has the unique role of contributing to or
preventing AD (113).
ADAM17 promotes cellular growth and acts as an
extracellular physiological convertase, shedding proteins
other than APP, including the EGF family of growth factors.
These include TGF-α and its receptor EGF (114). ADAM17
contributes to generation and maturation of TNF-α, EGR, and
some cell adhesion molecules [CAMS; (115)]. ADAM17 and
ADAM10 cleave Notch proteins to induce Notch signaling (116).
Further, acting anabolically, ADAM17 (and its kin, ADAM10)
(mal) function in the pathogenesis of cancers, rheumatoid
arthritis (117), and spinal cord injury (118). Besides converting
EGF (114), the peripheral immune mediator found in the Pardo
2017 study of children with autism (102), ADAM17 converts the
other cytokine mediators of autism found in the Pardo study:
IL-15 (119), FLT3 (120), CX3CL1(121), and CXCL8 (122).
Key Translation Signaling Pathways in
Inflammation
Key biochemical pathways involved in the immune response
are of great interest as they also play a central role in growth
and metabolism and may be involved in brain overgrowth in
autism. mTOR and MAPK pathways regulate immune function
(123). mTOR is composed of two structures, mTOR complex 1
(mTORC1) and mTOR complex 2 (mTORC2). More is known
about mTORC1 and its immediately upstream regulator Ras
homolog enriched in brain (RHEB). RHEB is controlled by
GTPase-activating protein (GAP), which involves the tuberous
sclerosis complex 1 (TSC1 and TSC2). When this complex is
phosphorylated by Akt or ERK1/2 (through phosphatidylinositol
3 kinase), this inhibits GAP activity so that RHEB is active,
which in turn activates mTORC1. Several cytokine and growth
factors activate mTOR including CD28, IL-1, IL-2, IL-4, and IL-
12. mTOR is involved in T-cell trafficking as upon recognition
of their antigen, CD8+ T cells activate mTOR and switch
to anabolism. Upon resolution of the infection, the antigen-
specific CD8+ cells contract and mTOR activity is decreased.
mTOR promotes differentiation, activation, and function in T-
cells, B-cells, and antigen presenting cells (123). The mTOR
anabolic biochemical pathway is of great interest in autism (124)
and in macrocephaly and autism (125). mTOR deregulation
also exists in AD (35). Evidence supports βAPP’s role in
activating T-lymphocytes. For example, transcription, translation
and secretion of βAPP have been induced via T-cell mitogen
stimulation of blood leukocytes (126). sAPPα modulation of the
immune system has been studied in an overproducing sAPPα
mouse model (31). These mice showed increased levels of CD8
T-cells and decreased memory T-cells suggesting that sAPPα
activates immunity.
The MAP kinase cascade is composed of three major groups:
the p38MAP kinases, the c-Jun NH2-terminal kinases (JNK) and
the extracellular signal-regulated protein kinases (ERK). MAP
kinases are important in lymphocyte development. Activation
of MAP kinases p38 and JNK produces inflammatory cytokines
including TNFα, IL-1, and IL-12. In turn, TNFα and IL-1
activate p38 and JNK MAP kinases. It has been shown that
JNK and p38 activation acts catabolically, leading to apoptosis
in AD (127). ERK regulates T cell activation and differentiation
(128). The growth factor signaling properties of the MAPK
pathways act anabolically, and are of interest in autism (124,
129, 130), with convergence of the MAPK pathway with calcium
signaling pathways reported as major contributors to autism
pathophysiology in a large gene set enrichment analysis (131).
We speculate that TNFα, elevated in autism, favors increased
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p38 and JNK resulting in increased brain matter, while decreased
TNFα promotes apoptosis via p38 and JNK in AD.
REGULATORY FACTORS
Purported mTOR Regulation in Autism and
AD
Neurotrophins, including nerve growth factor (NGF) and
brain-derived neurotrophic factor (BDNF) bind to and activate
tropomyosin-related kinases (TrkA, TrkB, or Trk C) which in
turn activate PI3K, phospholipase C (PLC), ERK1/2, and mTOR
(132). Neurotrophin signaling at multiple levels (epigenetic,
transcriptional, post-transcriptional, and post-translational)
determines cell fate, axonal and dendritic growth and pruning,
and the connection of neural networks (124). Abnormalities in
neurotrophins likewise exist in autism and AD (132).
mTOR is involved in promoting growth by means of protein
synthesis, actin cytoskeletal dynamics, energy homeostasis and
metabolism (124). Gene defects associated with upstream
regulators of mTOR (TSC1, TSC2, and PTEN), are associated
with autism and in many cases, macrocephaly. Constitutive
activation of upstream PI3K, Akt, and Ras, is anabolic, and
associates with macrocephaly, neuronal hypertrophy, increased
soma size and dendritic complexity of neurons (133). Products
of mTOR that contribute to translation such as p70 ribosomal S6
kinase 1 (Sgk1) and eukaryotic translation initiation factor 4 E-
binding proteins (4E-BPs) may play a role in autism (98, 134).
Over expression of eIF4E associates with an increase in complex
formation, long-term synaptic plasticity, increased dendritic
spine density, and behaviors similar to autism (135, 136). 4E-
BPs provide a brake on eukaryotic translation initiative factor
4E (EIF4E) which is a primary effector through which proteins
are synthesized. Phosphorylation of 4EBP by mTORC1 stops
this inhibition favoring EIF4E, and anabolic protein synthesis
(135). Huber’s view, based on research with FXS, supports
a model where FMRP represses a PI3K enhancer (PIKE) so
that mTOR is inhibited under basal conditions (137). Lack of
FMRP in FXS (and in some individuals with autism), would
also favor PIKE activation of mTOR and downstream Rho
GTPases including Rac1 and cofilin that in turn would cause actin
disassembly andmyelination (138). Recently, several studies have
identified a catabolic role of mTOR, and the upstream and
downstream components of its signaling, in the pathogenesis and
progression of AD (35). In some models, activation of mTOR
is interpreted as preventing autophagy of Aβ in the lysosomes.
However, treatment of AD with mTOR inhibitor rapamycin
was not recommended, as rapamycin decreases ADAM10, an
alpha secretase that may promote the protective, anabolic, non-
amyloidogenic pathway.
Myelination is metabolically demanding, and therefore, the
mTOR pathway, particularly the mTORC1 hub coordinating cell
metabolism, is a key signal for myelination (139). Besides its main
function as a regulator of mRNA translation, mTORC1 activates
lipid synthesis. Lipid is a major component of myelin. Further,
mTORC1 appears to coordinate protein and lipid synthesis
to make the membrane. It differentiates oligodendrocytes
from OCPs. Interestingly, hyperactivation of oligodendrocytes
after disruption of the TSC complex by deletion of TSC1
effects hypomyelination in the CNS and PNS (140, 141).
Hypomyelination and decreased oligodendrocytes were also
reported after deletion of TSC2 (142). These changes were
unexpected and not in keeping with the clinical picture of
macrocephaly and often megalencephaly with white matter
increases and tubers seen in tuberous sclerosis caused by TSC1
or TSC2 deletions, a single gene kin to autism. Therefore,
other factors besides overactivation of mTOR must lead to
excessive white matter in autism. Upstream from mTOR, Akt-1
is phosphorylated by PI3K in response to growth factors such as
Neuregulin 1, insulin growth factors and steroids that promote
myelination (143) The insulin growth factor 1 (IGF-1), when
phosphorylated, stimulates the P13K/Akt and MAPK pathways
and has been implicated in AD (144). IGF-1 acts anabolically,
stimulating α-secretase and reducing β secretase that has been
shown to decrease Aβ formation (145). In contrast, Aβ acts
catabolically, resulting in over-expression of PTEN which leads
to deactivation of P13K/Akt (146). Deletion of PTEN activates
the P13K/Akt pathway which results in increased myelination,
especially within the corpus callosum. Individuals with PTEN
syndrome show macrocephaly and autism (73). It appears that
there are several pathways that lead to myelination, perhaps
via activation of the Rho family proteins that in turn activate
myelination through sAPPα/α-secretases.
Purported MAPK Regulation in Autism and
AD
ERK 1/2, among the MAPK family members are involved with
cellular growth, chemokines, oxidative stress, and cytokines.
Single gene mutations associated with autistic-like syndromes
can also cause ERK1/2 activation including Tuberous sclerosis,
FXS, 16p11.2 and Neurofibromatosis. Macrocephaly and
increased white matter are often seen in these conditions (98).
However, of far greater interest to investigating the much larger
proportion of idiopathic autism, this pathway can be activated
by multiple stimuli, both internal and environmental. These
include interleukin-1β (IL-1β), TNF-α, and EGF (147), and
EGF receptor [EGFR; (148)], all which are elevated in autism.
The ADAM proteins play critical roles in EGFR signaling
(115, 122, 149). Several studies have found an association
between MAPK signaling and autistic traits. Indeed, genes
from the MAPK pathway were among the most frequent
represented in a large gene set analysis in autism (131). This
pathway has also been intensely researched in cancer studies,
as derangement in MAPK signaling may be important in the
development of cancer (150, 151). ERK and MAP kinase p38,
which are activated in response to inflammation or stress signals,
directly activates ADAM17 (152, 153). Sources of inflammatory
stimulation of MAPK include infection by Gram-negative
bacteria, and ensuing lipopolysaccharide (LPS) exposure. Several
mechanistic studies of LPS exposure in model animals showed
that LPS exposure induced both behavioral and neurological
autism-like symptoms, and that this induction was stronger
in male than female offspring (154–158). The MAPK pathway
is less implicated in pathogenesis of AD, although JNK and
P38 activation leads to apoptosis in AD (159). The neurogenic
properties of this pathway in association with those of the
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non-amyloidogenic pathway have been studied and will be
discussed below.
ERK1 and ERK2, downstream mediators of MAPK appear
to control CNS myelin thickness after oligodendrocyte
differentiation and initiation of myelin (160), as demonstrated by
in vivo loss of function studies (160) and in vivo gain of ERK1/2
function studies (161). In the latter, two lines of transgenic mice
with sustained activation of OPCs during early development
produced transient over-proliferation of OPCs, but resulted
in normal numbers of myelinating oligodendrocytes. This
was interpreted as ERK 1/2 effecting a biphasic response-first
an early expansion of OPC and a later promotion of myelin
growth. Another MAPK regulator, P38, directs oligodendrocyte
differentiation and myelination by way of gene transcription
(162). BDNF increases OPC proliferation and development
though the TrkB and MAPK pathway (163).
HYPERMYELINATION—A SOURCE OF
INCREASED WHITE MATTER IN AUTISM?
Having discussed how neuroinflammation, potentially causes
brain tissue edema and increased perfusion and how activated
signaling pathways associated with growth factors could
contribute to activation of white matter, we will now turn to the
potential contribution of myelination to increased white matter
in autism.
Oligodendrocytes ensheath multiple neuronal axons with
a lipid-rich myelin membrane. Myelin allows rapid synaptic
transmission, provides metabolic support and reduces the cost
of neuronal energy (164). There has been much effort to
understand myelin formation in the hopes of promoting myelin
repair for conditions such as multiple sclerosis. The belief
that remyelination “depends on signals that are similar to
those occurring in developmental myelination” (143), provides a
window into the origins of myelination and allows speculation
as to what myelinating processes may be in overdrive in
autism. During development, myelinating oligodendrocytes are
produced by OPCs within the subventricular zone (SVZ) of the
germinal matrix in the cortex. OPCs then undergo migration
and proliferation and extend through the entire nervous system.
OPCs retain the ability to migrate and to travel within the
CNS into adulthood where they continue to generate new
oligodendrocytes routinely (165), and after demyelinating injury
(166). In recent years it has been discovered that OPCs do
more than just give rise to oligodendrocytes, as “they are
found throughout the brain in numbers far greater than would
be needed for that role” (46). OPCs are the only glia that
receive synaptic input from neurons by way of an NG2 protein
(28). ADAM10, one of the purported alpha secretases, cleaves
this protein in response to neuronal network activity (28). It
appears that NG2 cleavage functions to strengthen long-term
potentiation (LTP) in the mouse somatosensory cortex, so, if
not a growth factor, overexpression of ADAM10 may yield
LTP aberration through OPC NG2 cleavage. OPC polarity and
directional migration also appears to be under the control of
NG2 glia (167), which features RhoA and Rac signaling. It is
worth noting here that mTOR regulates cofilin through Rho
family member Rac1, important in myelination (see below) and
implicated in autism (137). OPC embryonic development is
guided along endothelial cells by the powerful anabolic Wnt
signaling (168), a pathway associated with autism (169), and
regulated by the NOTCH canonical pathway (170) and βAPP
(171). There appear to be several paths to increased myelination,
and perhaps autism, should OPC N2 glial cells get excited.
Another view is that the consistent, abundant supply of
OPCs in the brain may be required for developing novel
motor skills (172). Myelination is a developmental process and
can continue into the third decade of life (173). Myelination
can change according to environmental experience (43). Early
studies reported oligodendroctyes increase by 27–33% in the
visual cortex of rats raise in enriched environments (174),
and the number of myelinated axons within the corpus
callosum increases in rats (175) and rhesus monkeys raised
in enriched environments (176). Myelination of specific areas
of the brain correlate with children’s cognitive ability (177)
and learning new tasks (178, 179). Indeed, activity dependent
communication between axon and oligodendrocytes may cause
increased oligodendrocyte production, and thicker and longer
myelin on axons (164). However, too much stimulation may
be deleterious. In rats, stress during late pregnancy causes
hypermyelination in the offspring (180). Maternal IgG antibodies
directed against fetal brain, considered immunologic stress, are
elevated inmothers of and children with autism (181–183). These
human maternal antibodies were injected into pregnant rhesus
monkeys and their offspring followed for 2 years (184, 185).
Their offspring showed subtle autistic behaviors; neuropathology
revealed enlarged brains notable for increased frontal lobe white
matter (184).
During OPC differentiation and myelination, OPC processes
change from thin membrane extensions to multi-layered, lipid
rich tubes ensheathing axons (164). The myelin sheath growth
occurs in two steps. First, an actin network supports the
leading edge clamping it between the axon and overlying
oligodendrocyte. Second, actin disassembly allows the myelin
membrane to spread around and along the axon (138). Actin
is disassembled by cofilin and gelsolin family proteins. Myelin
Basic Protein (MBP), an important component of CNS myelin,
is necessary for myelin wrapping. MBP promotes myelination
by releasing cofilin and gelsolin from the membrane and
deactivating actin. The Rho1/Rac polarity of the OCP NG2
demonstrates how oligodendrocyte differentiation might be
paired with axon wrapping (164). Pertinent to APP, MBP is a
potent inhibitor of Aβ fibrillary assembly (186). Similar to how
MBP functionally disassembles actin, the C-terminal of MBP1−64
binds to Aβ40 and Aβ42 peptides to inhibit fibril assembly. This
would deter developing AD. These authors Kotarba et al. note
that in human brain and in APP transgenic mice, Aβ peptides
usually are not seen in MBP rich white matter. Several studies
show increased levels of autoantibodies to MBP in the sera of
children with autism (187, 188), implying that cerebral MBP
levels may be high, although MBP has not been extensively
studied in autism brain tissue. In AD brain tissue, MBD was
degraded, suggesting destruction of white matter in AD (189).
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There is in vitro evidence that ADAM8 (not an alpha-secretase)
cleaves MBP (190, 191), which may indicate an inflammatory
reaction in AD (191). Therefore, reduction of MBP may lead
to increased Aβ peptides and brain atrophy in AD, whereas
increased MBP favors myelination and brain growth in autism.
Could these mechanisms in autism confer protection from AD?
This question recently has been discussed (32).
ADAM FAMILY α-SECRETASES
ADAM secretases perform many duties and play a role in CNS
myelination. For many years, it was known that ADAM family
members, particularly ADAM22, were important in peripheral
system myelination (192), although, ADAM17 inhibited
Schwann cell myelination (193). However, recently ADAM17
turned out to be “essential for oligodendrocyte development and
CNS myelination” (29). ADAM17 modulated OPC cell cycle
exit and oligodendrocyte lineage cell survival during subcortical
white matter development in transgenic mice. ADAM17
accomplished this by shedding EGFR ligands and performed
activation of oligodendrocytes during white matter development
by EGFR signaling. EGFR overexpression in ADAM17-deficient
OCPs restored cell survival and proliferation and subsequent
myelination. Unlike other reports of diseased states, this study
was distinguished by the analysis of oligodendrocytes during
FIGURE 1 | Multiple pathway stimulation of ADAM activity, leading to sAPPα
proliferation and notch stimulation. The contribution of white matter
overgrowth to autistic symptoms could begin with aberrant signaling of the
ERK/MAPK pathway. Multiple extracellular signal molecules have disrupted
levels in autism. This includes IL1β, EGF, and TNFα, which are elevated; and
TGFβ, which is depressed. In addition, the receptor for EGF (EGFR) is elevated
in autism. External stressors, such as LPS and reactive oxidizing species
(ROS) produced by oxidative stress, have been implicated in autism. Activity of
specific environmental toxins may exist but is still controversial. Once the
ERK/MAPK pathway has, by whatever means, been perturbed, this can
stimulate the ADAM proteins. The ADAMs not only cleave APP at the anabolic
cleavage site, producing sAPPα, but are also necessary for EGFR signaling
and stimulate NOTCH enzyme activity.
postnatal CNS myelination. The authors noted a divergence of
ADAM17 function between the CNS and PNS (29).
NOTCH
Notch signaling is essential for glial development and
CNS myelination (164, 170). Notch receptors are cleaved
intracellularly by secretases. In the CNS, Notch 1 receptor is
expressed by oligodendrocytes. Studies show that Notch 1 is
important for correct OPC temporal and spatial differentiation
(164). Contactin-1, a ligand of Notch, may promote OPC
differentiation within the expression of CNS myelin genes. The
contactin family of Ig cell adhesion molecules harbor several
members that have a genetic association with autism (194).
Following the canonical pathway, ADAM10 cleaves NOTCH
at the membrane which activates a piece that participates in
transcription. Activation of NOTCH within the non-canonical
pathway leads to OPC maturation and myelination. APP
interacts with Notch receptors and the APP gamma secretase
that produces the Aβ peptide is a Notch family member (195).
THE CASE FOR sAPPα DIRECTING
INCREASED WHITE MATTER IN AUTISM
Typical processing of βAPP greatly favors production of
sAPPα over Aβ peptide. Could an increase in α-secretase
activation overproduce myelin to the extent of inducing
FIGURE 2 | Stimulation of white matter overgrowth by elevated sAPPα (and
Notch). Elevated sAPPα enhances PI3K/Act/mTOR pathway activity, which
includes rho GTPase. The GTPase stimulates oligodendrocyte progenitors,
which require NOTCH activity to mature into oligodendrocytes. Elevated
oligodendrocytes would then contribute to hypermyelination, which would lead
to white matter overgrowth. The white matter overgrowth would contribute to
exacerbation of ASD endophenotypes, such as poor social functioning or
regression. Incidentally, this would also be reflected by macrocephaly and
megalocephaly.
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or exacerbating autism? As previously described, ADAM17
appears to act directly on oligodendrocyte development and
CNS myelination and in oligodendrocyte regeneration (29,
149). In vitro α-secretase activation produces an increased
number of mature oligodendrocytes and increased percentage
of myelinated axons with short internodes (196). One clinical
study of whole-exome sequencing in children with macrocephaly
and/or autism showed a surprising 10/21 patients with likely
pathogenic mutations along the PI3K/AKT-mTOR pathway
(125). It is possible that similar underlying, closely related
genetic mutations could push sAPPα into overdrive, resulting
in autism.
Increased sAPPα in autism could be a neuroinflammatory
response with resultant upregulation of the non-amyloidogenic
pathway. Bailey et al. (23) demonstrated increased sAPPα,
neuroinflammatory GFAP and gliosis in transgenic mice
designed to overexpress sAPPα in brain tissue. Upregulation
of GFAP was correlated with elevations in Interleukin 6 (IL-
6), gp130, and Notch1. The IL-6/gp130 pathway is considered
anabolic and promotes axonal sprouting of neurons and
activated astrocytes after entorhinal cortex lesion in rats
(197). Furthermore, ADAM17 participates in the cleavage of
inflammatory factors related to microglial activation (113) and in
reaction to injury (118). A prenatal insult would also increase the
expression of NMDA and glutamate receptors in the offspring.
High glutamate receptors activate the ERK signaling cascade.
Zeidan-Chulia et al. (198) proposed this model for autism after
performing a focused microarray analysis of genes belonging to
NOTCH, WNT and AD. They found upregulation of glutamate
ionotropic receptor NMDA type subunit 1 (GRIN1), and
MAP3K1, which activates the JNK and ERK pathways. Among
their conclusions, they proposed that epigenetic stress could
lead to increased NMDA receptors and increased calcium that
would stimulate ERK-dependent α-secretase activity. Activation
of ADAM17 by ERK (and P38 MAP kinase), for example,
can activate EGF receptor signaling which leads to enhanced
cell proliferation (152, 153). Higher levels of sAPPα would
then activate the PI3K/Akt/mTOR pathway also resulting in
aberrant brain growth. This model applies to brain cells in
general, not just white matter. However, as described above,
mTOR pathways favors myelination, except for the findings that
disruption of upper mTOR pathways result in hypomyelination
instead of hypermyelination (123). Therefore, other pathways
such as activation of ERK1/2 may be needed to explain increased
white matter in autism (Figure 1).
The intersection of sAPPα, its ADAM family secretases and
white matter expansion may be most convincingly proposed
by merging the above mentioned models (137, 198) with the
recent finding that the abundant OPC N2G is regulated by Rho
GTPases (164). α-secretase, activated by ERK receptor signaling,
in turn may activate PI3K/Akt/mTOR, and then Rho GTPases,
which would favor OPC stimulation (Figure 2). Subsequent
activation of cofilin with the disassembly of actin also favors
myelination, again stimulated by α-secretase. Recent findings
that netrin-1 appears to underlie OPC density and turnover
(199), and that OPCmigration along blood vessels is mediated by
WNT signaling (168), further opens the door to APP regulation
of myelination. APP regulates Netrin-1 mediated commissural
axon outgrowth (200), and Wnt signaling is protective against
Aβ peptide akin to the non-amyloidogenic pathway (201). Future
study of α-secretase in relation to autism may enable novel
treatments and avoid pitfalls in tested treatments for AD. One
example would be to determine if ADAM17 antibody could
reduce excessive brain growth and autistic symptoms, similarly to
the recent success of the drug BAN2401 (202), an antibody that
targets Aβ peptide.
CONCLUSION
Brain overgrowth is a consistent endophenotype in 20%
of individuals with autism. MRI volumetric studies showed
overgrowth for both gray and white matter for young
children (ages 2–6) with autism, coincidental to presentation
of autistic symptoms. The trajectory of brain growth slows
in adolescence and may show decreased growth at older
ages. Enlargement of brain matter in autism may be due to
a combination of elevated metabolic processes, migrational
abnormality, and/or neuroinflammation. Recognizing potential
contribution of the non-amyloidogenic pathway of βAPP
processing to brain enlargement in autism enables novel
adaptation of long-known AD pathway analyses to autism.
Increased sAPPα and the ADAM family α-secretases may directly
increase oligodendrocyte myelination or the neuroinflammatory
response that promotes axonal sprouting of neurons and
astrocyte activation. Consequently sAPPα and the ADAM
family α-secretases, activated ERK receptor signaling, can
activate P13K/AKt/mTOR. Resulting activation of Rho GTPases
would favor OPC stimulation, thus enhancing myelination
by activation of cofilin. Identification of new roles for AD
pathways in autism may lead to new treatments for this
enigmatic disorder.
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